Site Map  |  Privacy Policy

Aridis Pharmaceuticals  © 2012   Le3 Web Designs

Convenient, Effective Therapies

for Infectious Diseases

February 8th, 2012. Aridis receives notice of award of a NIH grant to develop room temperature stable oral thin film formulation for vaccine against anthrax and plague.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

September 19th, 2011. The National Institute of Allergy and Infectious Diseases (NIH) awards Aridis a $3m Phase 2 STTR grant to complete preclinical development and file an IND of anti-pseudomonas aeruginosa monoclonal antibody AerucinTM.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

July 6th, 2011. Aridis named as sub-recipient  of a grant award from the National Institutes of Health’s Integrated Preclinical/Clinical Program for HIV Topical Microbicides to develop advanced formulation for the delivery of monoclonal antibody-based anti-infectives.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

November 4th, 2011. Interim results of a Phase 1 pharmacokinetic and safety clinical trial study of intravenous gallium nitrate citrate in cystic fibrosis patients shows acceptable safety profile and suggestion of a biologic response with microbiology and lung function changes.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

June 13th, 2011. Aridis announces the addition of Professor Kenneth Raymond (Univ. California, Berkeley) to its Scientific Advisory Board.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

March 11th, 2011. Aridis’ gallium based anti-infective drug candidate exhibits strong potency against  highly antibiotics resistant New Delhi metallo-beta-lactamase 1 (NDM-1) Klebsiella pneumoniae bacterial strain.

News

Anti-Infectives Aerucin

Formulation Technologies

Anti-Infectives Panaecin

>> More News